Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Shanghai Shen Lian Biomedical's share price is ¥8.41.
Shanghai Shen Lian Biomedical's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was ¥0.63. Hence, Shanghai Shen Lian Biomedical's PS Ratio for today is 13.26.
Good Sign:
Shanghai Shen Lian Biomedical Corp stock PS Ratio (=12.54) is close to 1-year low of 11.4.
The historical rank and industry rank for Shanghai Shen Lian Biomedical's PS Ratio or its related term are showing as below:
SHSE:688098'
s PS Ratio Range Over the Past 10 Years
Min: 3.98 Med: 11.57 Max: 39.97
Current: 13.28
During the past 13 years, Shanghai Shen Lian Biomedical's highest PS Ratio was 39.97. The lowest was 3.98. And the median was 11.57.
SHSE:688098's PS Ratio is ranked worse than 57.8% of 929
companies
in the Biotechnology industry
Industry Median: 9.25
vs SHSE:688098: 13.28
During the past 13 years, Shanghai Shen Lian Biomedical's highest 3-Year average Revenue per Share Growth Rate was 5.70% per year. The lowest was -33.60% per year. And the median was -4.50% per year.
Shanghai Shen Lian Biomedical (SHSE:688098) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Shanghai Shen Lian Biomedical PS Ratio Related Terms
Shanghai Shen Lian Biomedical PS Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SHSE:688098 vs VRTX, REGN, RVMD: PS Ratio Comparison
For the Biotechnology subindustry, Shanghai Shen Lian Biomedical's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shanghai Shen Lian Biomedical PS Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Shanghai Shen Lian Biomedical's PS Ratio distribution charts can be found below:
* The bar in red indicates where Shanghai Shen Lian Biomedical's PS Ratio falls into.
Shanghai Shen Lian Biomedical PS Ratio Calculation
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Shanghai Shen Lian Biomedical's Share Price of today is ¥8.41. Shanghai Shen Lian Biomedical's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥0.63.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Shanghai Shen Lian Biomedical (SHSE:688098) has a PS Ratio of 13.26 as of Aug. 06, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Shanghai Shen Lian Biomedical and its competitors. This is 15% above median its historical median of 11.57. Over the past decade, Shanghai Shen Lian Biomedical's PS Ratio has ranged from 3.98 to 39.97. According to the industry distribution chart, Shanghai Shen Lian Biomedical ranks #537 out of 929 companies in the Biotechnology industry, placing it in the top 57.8%.
Is Shanghai Shen Lian Biomedical's PS Ratio too high?
Shanghai Shen Lian Biomedical's current PS Ratio of 13.26 is 15% above median its 10-year median of 11.57. Over the past 10 years, this metric has ranged from a low of 3.98 to a high of 39.97. The Biotechnology industry median PS Ratio is 9.25. Shanghai Shen Lian Biomedical's value of 13.26 is 43.4% above this industry median. Based on the distribution chart, Shanghai Shen Lian Biomedical ranks #537 out of 929 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Shanghai Shen Lian Biomedical has a GF Score™ of 70/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Shanghai Shen Lian Biomedical's PS Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Shanghai Shen Lian Biomedical ranks #537 out of 929 companies for PS Ratio. This places Shanghai Shen Lian Biomedical in the lower half of its industry. The industry median PS Ratio is 9.25. Shanghai Shen Lian Biomedical's value of 13.26 is 43.4% above this benchmark. Historically, Shanghai Shen Lian Biomedical's own PS Ratio has ranged from 3.98 to 39.97 over the past decade. While the company's 10-year median is 11.57 vs. the industry median of 9.25, Shanghai Shen Lian Biomedical has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Biotechnology company?
The median PS Ratio among Biotechnology companies is 9.25, based on 929 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Shanghai Shen Lian Biomedical's current PS Ratio of 13.26 is 43.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Shanghai Shen Lian Biomedical and its competitors. For the Biotechnology industry, the median PS Ratio is 9.25 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Shanghai Shen Lian Biomedical's current PS Ratio is 13.26, which is 15% above median its own 10-year median of 11.57. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shanghai Shen Lian Biomedical stock overvalued right now?
Based on GuruFocus' analysis, Shanghai Shen Lian Biomedical (SHSE:688098) is currently considered Significantly Overvalued. The stock's GF Value™ is ¥5.85, compared to a current price of ¥8.41 — trading 43.8% above its estimated fair value. The current PS Ratio is 13.26, which is 15% above median its 10-year median of 11.57 and 43.4% above the Biotechnology industry median of 9.25. Shanghai Shen Lian Biomedical's overall GF Score™ is 70/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Shanghai Shen Lian Biomedical (SHSE:688098), the current PS Ratio is 13.26 as of Aug. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Shanghai Shen Lian Biomedical (SHSE:688098) Overvalued in 2026?
Based on GuruFocus' analysis, Shanghai Shen Lian Biomedical stock appears to be overvalued.
The current stock price of ¥8.41 is trading 43.8% above its estimated GF Value™ of ¥5.85.
GuruFocus considers Shanghai Shen Lian Biomedical to be Significantly Overvalued.
Key valuation signals for SHSE:688098:
PS Ratio: 13.26 (15% above median its 10-year median of 11.57)
GF Value™: ¥5.85 vs. price of ¥8.41 (43.8% above fair value)
Industry Position: 43.4% above the Biotechnology median (#537 of 929)
No single metric tells the full story. See the SHSE:688098 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688098 has been successfully added to your 
